Yinyin Li | Principal Scientist
Genentech
Yinyin Li got her PhD degree from Texas A&M university and completed postdoc training at Stanford University, where she focused on innate and adaptive immune response in autoimmune and inflammatory disease. Currently, she is a Principal Scientist in the Biochemical and Cellular Pharmacology Department at Genentech and serves as the group leader for functional screening and characterization of lead candidates to advance drug discovery. Additionally, she is a core member of the gRED immunogenicity risk assessment team, where she leads efforts to assess and mitigate immunogenicity risk for biotherapeutics.
Appearances:
Festival of Biologics Day 2 @ 16:50
From Discovery to Clinic: Immunogenicity Risk Assessment in Autoimmune Disease Biologics
The development and use of biotherapeutics in autoimmune diseases have revolutionized treatment paradigms, offering targeted interventions with the potential for improved patient outcomes. However, the immunogenicity of these biologics remains a critical challenge, as anti-drug antibody (ADA) responses can affect therapeutic efficacy and safety.
This presentation will explore the strategies for assessing immunogenicity risk in biotherapeutics used for autoimmune diseases, emphasizing the importance of early and thorough evaluation, underscoring the necessity for tailored strategies to enhance drug safety and efficacy.
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events